Clinical trials: Secondary-progressive Multiple Sclerosis
Secondary Progressive Multiple Sclerosis
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with…
- Trial name
- NCT07299019
- Testing
- Orelabrutinib
- Where
- 69 sites in United States, Australia and 14 more
- Volunteers
- 990 people
- Sponsor
- Zenas BioPharma (USA), LLC
Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy…
- Conditions
- Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Trial name
- BEAT-MS (NCT04047628)
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT)
- Where
- 23 sites in United States
- Volunteers
- 156 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Secondary Progressive Multiple Sclerosis (SPMS)
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
The purpose of this study is to provide efficacy and safety data for remibrutinib in patients with secondary progressive multiple sclerosis (SPMS)
- Trial name
- REMASTER (NCT07225504)
- Testing
- Remibrutinib (blinded), Remibrutinib (Open label)
- Where
- 296 sites in United States, Argentina and 34 more
- Volunteers
- 1,275 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Primary Progressive Multiple Sclerosis
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy
This is a global, multicenter, Phase 1b/2 study evaluating the safety and efficacy of C-CAR168, an autologous anti-CD20/BCMA chimeric antigen receptor T-cell therapy, in participants with progressive multiple sclerosis refractory…
- Conditions
- Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progress Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS)
- Trial name
- NCT07825389
- Testing
- C-CAR168
- Where
- 2 sites in United States
- Volunteers
- 119 people
- Sponsor
- AbelZeta Inc.
Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis
Cladribine Tablets as an Exit Therapy Strategy
The objective of the study is to evaluate the effectiveness of CladT, in terms of disease stability and safety, as the last treatment option in ageing MS patients vs treatment continuation and discontinuation This observational…
- Conditions
- Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Trial name
- CLADREXIT (NCT06887426)
- Testing
- Cladribine
- Where
- France
- Volunteers
- 450 people
- Sponsor
- University Hospital, Strasbourg, France
Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS)
Evaluation of an Online, On Demand Multimodal Wellness Program to Reduce Fatigue and Improve Quality of Life in Progressive Multiple Sclerosis.
The goal of this clinical trial is to learn if an online wellness program can lower fatigue and improve mood and quality of life in people with progressive multiple sclerosis who are 45 to 70 years old and are experiencing…
- Trial name
- DEW (NCT07831928)
- Testing
- Online wellness course and online exercise platform, Usual Care Group
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- University of Iowa
Primary Progressive Multiple Sclerosis, Primary Progressive MS
A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
The goal of this Phase 2 clinical trial is to investigate the safety and tolerability of SUN-627 in men and women aged 18-70 years old with a diagnosis of non-active SPMS/PPMS.
- Conditions
- Primary Progressive Multiple Sclerosis, Primary Progressive MS, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive MS (SPMS)
- Trial name
- NCT07840326
- Testing
- SUN-627
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sundance Biosciences, Inc.
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS)
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
The goal of this clinical trial is to treat male and female participants with two types of Multiple Sclerosis (MS) called primary progressive or secondary progressive MS.
- Conditions
- Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive
- Trial name
- IMPACT-MS (NCT07477639)
- Testing
- TRX319, Bendamustine
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- Tr1X, Inc.
Relapsing Remitting Multiple Sclerosis, Primary Progressive Multiple Sclerosis
SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis
The study seeks to investigate safety and efficacy of ixazomib (NINLARO), a proteasome inhibitor, in multiple sclerosis (MS). Participants will receive either ixazomib capsules or placebo capsules for up to 24 months.
- Conditions
- Relapsing Remitting Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Trial name
- SIZOMUS (NCT03783416)
- Where
- United Kingdom
- Volunteers
- 72 people
- Sponsor
- Queen Mary University of London
Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive
A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS
The study is an investigator-run, study following participants for 2 years with twice-daily remibrutinib. MRI is the main endpoint. Safety, tolerability, and efficacy are secondary endpoints.
- Conditions
- Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive, Multiple Sclerosis (MS) Primary Progressive
- Trial name
- RemiSeven (NCT07222956)
- Testing
- Remibrutinib (Open Label)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Moein Amin
Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis
The DanNORMS study is a phase 3, non-inferiority clinical trial examining whether treatment of active multiple sclerosis with rituximab is non-inferior to ocrelizumab regarding efficacy and safety.
- Conditions
- Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
- Trial name
- DanNORMS (NCT04688788)
- Testing
- Rituximab, Ocrelizumab, Fexofenadine
- Where
- 11 sites in Denmark
- Volunteers
- 600 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
This is a Phase 3 extension, global, multicenter study to assess the long-term safety and tolerability of tolebrutinib in adult participants (aged ≥18 years) with RMS, PPMS, or NRSPMS who were previously enrolled in the Phase 2b…
- Conditions
- Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
- Trial name
- NCT06372145
- Testing
- Tolebrutinib, Teriflunomide
- Where
- 352 sites in United States, Argentina and 45 more
- Volunteers
- 2,500 people
- Sponsor
- Sanofi
Secondary Progressive Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive
Novel Imaging Markers in SPMS
This pilot study takes the innovative approach of using ultrasmall superparamagnetic iron oxide (USPIO) nanoparticle enhanced MRI to measure activity of the innate immune system within MS lesions.
- Conditions
- Secondary Progressive Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis
- Trial name
- NCT05357833
- Testing
- Ferumoxytol infusion, Gadoteridol, MRI Brain and Cervical Spine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Utah
Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis
Safety and Efficacy of S103 Cells in Progressive/Refractory Multiple Sclerosis
This study is a single-center, open-label, single-arm, exploratory clinical study to evaluate the safety, tolerability, and preliminary efficacy of S103（BCMA-CAR T ）cells in the treatment of progressive or refractory multiple…
- Conditions
- Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis, Multiple Sclerosis (MS) Secondary Progressive, Refractory Multiple Sclerosis
- Trial name
- RESET-MS (NCT07587125)
- Testing
- S103 cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Xijing Hospital
Secondary Progressive Multiple Sclerosis
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
Foralumab is a human anti-CD3 monoclonal antibody being developed for the treatment of autoimmune and inflammatory diseases. The goal of this Phase 2a, randomized, double-blind placebo-controlled, multicenter dose-ranging study…
- Trial name
- NCT06292923
- Testing
- Foralumab
- Where
- 7 sites in United States
- Volunteers
- 54 people
- Sponsor
- Tiziana Life Sciences LTD
Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting
Acute Intermittent Hypoxia Combined With Gait Training in Multiple Sclerosis
This interventional, randomized, sham-controlled study will examine whether Acute Intermittent Hypoxia (AIH) delivered immediately before Myoelectric Interface Neurorehabilitation Training (MINT)-based locomotor training improves…
- Conditions
- Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) Secondary Progressive
- Trial name
- MINT (NCT07631923)
- Testing
- Acute Intermittent Hypoxia (AIH), Myoelectric Interface Neurorehabilitation Training (MINT)
- Volunteers
- 35 people
- Sponsor
- Shirley Ryan AbilityLab
Active Secondary Progressive Multiple Sclerosis
Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy
This is an observational, multicenter, single-arm, prospective study conducted in Italy
- Trial name
- ITASIA (NCT05376579)
- Testing
- siponimod
- Where
- 24 sites in Italy
- Volunteers
- 134 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis
PHOMS Study is a randomized, controlled, open-label, prospective, and multicentric clinical trial involving outpatients diagnosed with Secondary Progressive Multiple Sclerosis (SPMS) or Relapsing-Remitting Multiple Sclerosis…
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
- Trial name
- PHOMS (NCT05168384)
- Testing
- Extracorporeal Photopheresis, MS standard of care
- Where
- United Arab Emirates
- Volunteers
- 15 people
- Sponsor
- Abu Dhabi Stem Cells Center
Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM)
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
A Phase 1 study of HBI0101 BCMA-CART in B-Cell Mediated Autoimmune Rheumatic Diseases. The goal of the study is evaluation of safety and identification of the maximum HBI0101 CART dose that may be administered safely to patients…
- Conditions
- Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM), Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
- Trial name
- NCT07085676
- Testing
- HBI0101 CART
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- Polina Stepensky
Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Functional Outcomes From Diets in Multiple Sclerosis
The purpose of this study is to test the effects of two dietary interventions, glycemic load and calorie restriction, on physical function, cognition, pain, fatigue, mood, and anxiety in adults with multiple sclerosis (MS).
- Trial name
- FOOD_for_MS (NCT05327322)
- Testing
- Glycemic load, Calorie restriction, Behavioral support
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- University of Alabama at Birmingham